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Angiotensin-converting enzyme (ACE) is primarily local-
ized (>90%) in various tissues and organs, most notably
on the endothelium but also within parenchyma and
inflammatory cells. Tissue ACE is now recognized as a
key factor in cardiovascular and renal diseases. Endo-
thelial dysfunction, in response to a number of risk
factors or injury such as hypertension, diabetes mellitus,
hypercholesteremia, and cigarette smoking, disrupts the
balance of vasodilation and vasoconstriction, vascular
smooth muscle cell growth, the inflammatory and oxi-
dative state of the vessel wall, and is associated with
activation of tissue ACE. Pathologic activation of local
ACE can have deleterious effects on the heart, vascula-
ture, and the kidneys. The imbalance resulting from
increased local formation of angiotensin II and in-
creased bradykinin degradation favors cardiovascular
disease. Indeed, ACE inhibitors effectively reduce high
blood pressure and exert cardio- and renoprotective
actions. Recent evidence suggests that a principal target
of ACE inhibitor action is at the tissue sites. Pharmaco-
kinetic properties of various ACE inhibitors indicate that
there are differences in their binding characteristics for
tissue ACE. Clinical studies comparing the effects of an-
tihypertensives (especially ACE inhibitors) on endothelial
function suggest differences. More comparative experi-
mental and clinical studies should address the signifi-
cance of these drug differences and their impact on
clinical events. 2001 by Excerpta Medica, Inc.
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INTRODUCTION
Our awareness and appreciation of the role oftissue angiotensin-converting enzyme (ACE) in
endothelial function and vascular health has begun to
influence the treatment of cardiovascular and renal
disorders. The results of experimental and clinical
research have provided the rationale for intervening in
the underlying pathophysiologic processes associated
with activated tissue ACE in conditions such as con-
gestive heart failure, coronary artery disease, hyper-
tension, and nephrosclerosis. Extensive evidence in-
dicates that ACE inhibition favorably affects the heart,
the vasculature, and the kidney, the results of which
are associated with improved patient outcomes. This
consensus report will provide an extensive review of
the biology and function of tissue ACE, its role in the
pathophysiology of cardiovascular disease, the impor-
tance of tissue ACE as a therapeutic target, and evi-
dence from clinical trials for the beneficial effects of
tissue-ACE inhibition. The article will also examine
the pharmacologic properties of ACE inhibitors and
explore the potential clinical effects related to differ-
ences in binding for tissue ACE.
TISSUE ANGIOTENSIN-CONVERTING ENZYME: BIOLOGY,
FUNCTION, AND PATHOPHYSIOLOGY
The structure of ACE is well known, and the
enzyme’s predominant localization in tissue, rather
than plasma, was established nearly 30 years ago.
Despite this knowledge and an abundance of recent
experimental data, the role of genetic variability in
ACE activity has yet to be fully resolved.
BIOCHEMISTRY AND GENETICS
OF ACE
ACE: ACE is a zinc metallopeptidase that catalyzes
1 of the main steps in the renin cascade—the conver-
sion of angiotensin I (Ang I) to angiotensin II (Ang II),
a potent vasoconstrictor. ACE is also involved in the
inactivation of the vasodilator hormones, bradykinin
and substance P.1 The ACE enzyme exists in 2 forms,
a high molecular weight form (170 kDa) found in
endothelial, epithelial, and neuronal cells, and a low
molecular weight form (90 kDa) found in germinal
cells. The 2 forms are encoded by 2 different messen-
ger RNAs corresponding to molecular sizes of 2.0
kilobase (kb) and 4.3 kb. ACE is found in the plasma
and in a number of tissues including blood vessels,
heart, kidney, brain, and the adrenal gland.2 Somatic
ACE (the form of ACE made by endothelium and
other somatic tissues) is a single polypeptide chain
that contains 2 homologous protein domains. Each
domain is independently catalytic with roughly equiv-
alent affinities for Ang I. ACE is synthesized with an
amino terminal signal sequence. This leads to export
of both catalytic domains from the cell, but the last
carboxyl-terminal portion of the molecule is hydro-
phobic and anchors the protein within the cell mem-
brane. Thus, ACE is an ectoenzyme with both cata-
lytic domains outside of the cell (Figure 1).
Plasma versus tissue ACE: Biochemical measure-
ments of ACE activity illustrate that ACE is a tissue-
based enzyme.3 Indeed, 10% of ACE is found cir-
culating in the plasma.3 The functional importance of
tissue-based ACE has been demonstrated in geneti-
cally altered mice devoid of tissue ACE but having
substantial plasma ACE levels. These mice have dem-
onstrated an inability to activate their renin–angioten-
sin system and consequently develop marked hypo-
tension.4 The precise function of plasma ACE is un-
clear. However, because it represents only a small
proportion of the body’s total ACE activity, its role is
thought to be minimal.
Role of the genetic variations of ACE: The chromo-
somal locus of the ACE gene has been linked to the
variability of ACE activity and arterial hypertension,
as well as left ventricular mass (independent of blood
pressure) in several rodent breeding experiments.5,6 In
addition, genetic factors may also regulate vasculature
ACE expression and production in humans. In 1990,
Rigat et al7 described an insertion/deletion polymor-
phism of the ACE gene that accounted for 40% of the
interindividual variation in serum and cardiac ACE
activity.7–9 ACE levels are highest in individuals who
are homozygous for the D allele, lowest in those
homozygous for the I allele, and intermediate in I/D
heterozygous individuals. Since 1990, the ACE D
allele has been associated with a number of disease
states for which activation of the renin–angiotensin
system has been implicated in playing a role, includ-
ing acute myocardial infarction (MI) in low-risk pa-
tients,10 left ventricular hypertrophy,11–13 and progres-
sive diabetic nephropathy.14 This association has been
attributed to increased formation of Ang II in individ-
uals who carry the ACE D allele. These results have
not been duplicated by other investigators.15,16 It has
been suggested that in healthy subjects, negative feed-
back inhibition may neutralize the genetically en-
hanced expression of singular components in the Ang
II synthetic cascade.17 By contrast, the ACE DD ge-
notype may play a substantial role in the development
of left ventricular hypertrophy when the cardiac
growth machinery is activated. This hypothesis is il-
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lustrated by recent data from Montgomery et al18 in
which young healthy subjects were studied before and
after a rigorous exercise protocol. Only those partici-
pants who carried the ACE deletion allele displayed
an increase in left ventricular mass. Thus, the ACE
genotype may act only under specific conditions, sug-
gesting an interaction between altered hemodynamics,
ACE, or other genetic cofactors in the modulation of
left ventricular mass. In agreement with this notion are
the observations of Pinto et al19 and Ohmichi et al20
who both found that pathologic remodeling early after
MI occurs predominantly in those subjects with the
ACE DD genotype. Furthermore, transgenic rats with
high levels of cardiac ACE expression have normal
(or even smaller) hearts, as long as these animals are
housed under physiologic conditions. However, car-
diac growth and diastolic dysfunction were augmented
in the same ACE transgenic rats when the animals
were stressed by abdominal aortic banding and sub-
sequent cardiac pressure overload.21 However, the
ACE gene polymorphism has not been consistently
associated with hypertension or the prevalence or ex-
tent of coronary artery disease or MI.22,23 Thus, the
role of the genetic variability of ACE remains to be
fully elucidated.
TISSUE ACE, THE CARDIOVASCULAR
SYSTEM, AND THE KIDNEYS
The importance of tissue ACE in the pathophysi-
ology of cardiovascular disease is reflected by findings
that, despite the existence of alternative Ang II path-
ways, marked ACE induction occurs in almost all
models of cardiac injury. Within the vasculature, tis-
sue ACE plays a critical role in endothelial function
through the direct pleiotropic actions of Ang II and
also through a bradykinin-dependent mechanism.
There is also substantial evidence that in atheroscle-
rosis, plaque represents an important target of ACE
inhibitor action. Finally, the kidneys are especially
susceptible to the toxic effects of chronically elevated
levels of Ang II; thus, the exuberant response to injury
may ultimately lead to renal failure.
Tissue ACE and the heart: TISSUE SITES OF ACE EX-
PRESSION: ACE activity is distributed in a tissue and
cell-type specific fashion.3 Very high levels are found
in the capillary bed of the lungs.24 Because of its high
ACE levels, the pulmonary vasculature—albeit a tis-
sue site—is considered an integral part of the classic
circulating renin–angiotensin system.24 In contrast,
some tissues, including the heart, express relatively
low levels of ACE, at least under physiologic condi-
FIGURE 1. Angiotensin-converting enzyme (ACE; EC 3.4.15.1) Schematic drawing shows the
structure of ACE. There is a catalytic site on each extracellular lobe, each of which binds a
zinc (Zn2) atom. (Adapted with permission from Hypertension).159
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tions.3,25 Within the normal heart, the right atrium
elaborates a moderate density of ACE, which is higher
than that of the left atrium and the ventricles.26 The
vast majority of immunohistochemical ACE staining
is found in the endothelium of large and small cardiac
arteries and arterioles, whereas only half the capillar-
ies are immunoreactive, and venous vessels are almost
completely devoid of the enzyme.26,27 Other sites of
cardiac tissue ACE expression include the endocardial
layer and the cardiac valves.26 Very little, if any, ACE
is found in normal adult cardiac myocytes in situ.
LOCALIZATION AND REGULATION OF ACE IN HEART
DISEASE: After our initial observation of ACE upregu-
lation in pressure-overloaded, hypertrophied hearts,25
marked ACE induction has been found in virtually all
models of cardiac injury including volume over-
load,28,29 MI,30,31 and heart failure.32 Additionally,
increased cardiac ACE levels have been correlated
with the aging process.33 Elevated wall stress is be-
lieved to be a critical factor for cardiac ACE induc-
tion, because elevated enzyme levels were found ex-
clusively in the affected ventricle.34 Interestingly,
ACE upregulation is not restricted to the vascula-
ture,27 because fibroblasts and myocytes are also re-
cruited for ACE expression in injured hearts.27,31,32
Likewise, cardiac myocytes in cell culture have been
reported to express ACE and are able to generate Ang
II locally, especially in response to mechanical
stretch.35 Moreover, macrophages invade injured
myocardium and carry high levels of ACE activity to
interstitial sites where Ang II, the product of ACE,
accumulates.27,36,37 In addition, mast cells in cardiac
tissue are another source of tissue Ang II through the
action of chymase.38 The role of tissue ACE in the
heart is summarized in Figure 2.
Whereas cardiac ACE increases in the failing
heart, pulmonary ACE tends to decrease when pulmo-
nary congestion complicates the condition.39 These
opposing regulatory steps may protect Ang I from
conversion/degradation in the lung and increase ACE
substrate in the heart.39
KINETICS AND MECHANISMS OF CARDIAC ANG II FOR-
MATION: During a single passage through the coronary
system, approximately 3% to 10% of Ang I is con-
FIGURE 2. Origins and actions of myocardial tissue angiotensin-converting enzyme (ACE)–angiotensin II (Ang II). AT1R  angiotensin
II type 1 receptor; AT2R  angiotensin II type 2 receptor; NE  norephrine.
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verted to Ang II.25,40 However, these measurements
may only reflect vascular conversion. More precise
insights on the intracardiac events leading to Ang II
generation were revealed by experiments that used
intracoronary infusions of minute concentrations of
radiolabeled (exogenous) Ang I or Ang II followed by
measurements of native (endogenous) as well as la-
beled angiotensins in the interstitial fluid, the cellular
compartment, and the coronary effluent.8,41 These ex-
periments revealed that angiotensinogen and renin are
extracted from the coronary circulation.42,43 Indeed,
cardiac concentrations of renin may substantially ex-
ceed renin levels in the plasma, suggesting an active
mechanism for cardiac renin accumulation.42,43 In ad-
dition, there appears to be local generation of angio-
tensinogen and renin, at least during disease condi-
tions.44,45
These kinetic studies document that 80% of Ang
I found in the cardiac interstitium is formed locally by
renin (which is largely taken up from the circulation)
cleaving angiotensinogen (which is both locally
formed and taken up from the circulation).40,41 Like-
wise, most of the Ang II found in the heart is synthe-
sized in situ. Specifically, the conversion of Ang I to
Ang II appears to be mediated by tissue ACE rather
than blood-derived enzymes.46 Consequently, the tis-
sue levels of Ang II are several times higher than the
circulating levels.36 It is conceivable, therefore, that
the local levels of ACE activity reflect the cardiac Ang
II concentrations.
In experimental models and in humans, the cardiac
conversion of Ang I to Ang II is largely blocked by
ACE inhibitors.37,46–49 By contrast, in ex vivo mem-
brane preparations of cardiac tissue (human and rat),
the conversion of Ang I to Ang II occurs largely
independently of ACE.50,51 Chymase, a mast cell en-
zyme with high affinity for Ang I, has been shown to
catalyze this reaction and chymase inhibitors were
effective in its inhibition.38 This apparent discrepancy
between in vivo and in vitro data51 may have been
resolved by the findings of Kokkonen et al,52 who
demonstrated that interstitial fluid completely inhibits
chymase activity, whereas ACE remains active under
these same conditions. Despite this finding, chymase
may still be important, and further investigation is
necessary to define its role in the formation of Ang II
in humans.
FUNCTIONAL ROLE OF ACE IN THE NORMAL AND FAIL-
ING HEART: The normal development of the heart does
not require the functional integrity of the cardiac re-
nin–angiotensin system. Thus, genetically altered
mice lacking cardiac ACE do not experience cardiac
pathology.53 Furthermore, Ang II is not required for
the maintenance of normal cardiac function.54 In this
regard, the role of the cardiac renin–angiotensin sys-
tem differs from that of the renal renin–angiotensin
system, which requires Ang II for normal kidney
development.55
In the failing heart, however, activation of the
renin–angiotensin system may have a series of func-
tional implications. Ang II has been shown to enhance
protein synthesis independently of load in the intact
heart as well as in the isolated myocyte.56,57 Ang II,
then, is considered to be an important factor contrib-
uting to the development of cardiac hypertrophy. ACE
appears to be involved in this process because, on the
one hand, the activity of the enzyme is enhanced in
hypertrophied hearts and on the other hand, inhibition
of the enzyme may cause regression of left ventricular
hypertrophy, even when the pressure or volume over-
load persists.58,59 Even more strikingly, the inhibition
of cardiac ACE with a high tissue-affinity ACE inhib-
itor (quinapril) prevented the development of volume
overload hypertrophy more efficiently than an ACE
inhibitor (enalapril) with low affinity for tissue
ACE.28,60 Moreover, tissue-ACE activity is involved
in the pathogenesis of coronary vascular and myocar-
dial structural changes induced by long-term blockade
of nitric oxide synthesis.61
Ang II not only induces hypertrophy of cardiac
myocytes but also hyperplasia of cardiac fibroblasts.62
Accordingly, the activation of the cardiac renin–an-
giotensin system and specifically, cardiac ACE, may
contribute to the development of cardiac fibrosis.62 It
has been demonstrated that fibrotic areas of the heart
display the highest levels of cardiac ACE activity31,32
and that fibroblasts themselves generate Ang II.63
ACE inhibitors, on the other hand, may prevent the
accumulation of extracellular matrix proteins and the
development of fibrosis of the heart (Figure 3), even
when pressure overload persists.64,65 The intimate
communication between cardiac fibroblasts and myo-
cytes was elegantly demonstrated in chimeric mice
that had Ang II receptor type 1A gene null mutant
cells and Ang II receptor type 1A gene intact cells
expressing the lacZ gene. Proliferating cardiac fibro-
blasts were present predominantly in areas of Agtr1a
intact cardiomyocytes. Therefore, an intact cardiac
renin–angiotensin system appears to be a requirement
for local proliferation of fibroblasts and the conse-
quent development of fibrosis.66
Ang II has also been shown to induce apoptosis of
cardiac myocytes, whereas cardiac fibroblasts are
fairly resistant to the effects of Ang II on cell death.67
Specifically, the enhanced local renin–angiotensin
system decreases the bcl-2-to-BAX protein ratio in
cardiomyocytes, thus decreasing the resistance to un-
dergo programmed cell death.67 There appears to be a
vicious circle, given that an apoptosis-related protein,
p53, induces the local renin–angiotensin system.68 In
fact, the induction of cardiac ACE parallels the ap-
pearance of apoptosis in the pressure-overloaded
heart.69 Again, use of ACE inhibitors has been shown
to prevent apoptosis of cardiac myocytes in pressure-
overloaded hearts.69
The activation of tissue ACE in cardiac remodeling
has direct functional consequences. Ang II causes a
depression of diastolic function in the hypertrophied
heart.25,47 Likewise, perfusion of isolated hearts with
Ang I, followed by intracardiac conversion to Ang II,
causes an increase in left ventricular end-diastolic
pressure, suggesting that local ACE may facilitate this
response.47 ACE inhibitors infused into the coronary
arteries of isolated experimental hearts or hearts of
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patients with aortic stenosis caused a significant im-
provement in diastolic function.47,70,71 This response
is even amplified in hearts exposed to an ischemia/
reperfusion injury.72 Conversely, the effects of Ang II
on systolic function in the failing ventricles are min-
imal.54
Local generation of Ang II may also increase the
vascular tone of the coronary bed. Specifically, in
patients with dilated cardiomyopathy, intracoronary
enalaprilat induced a significant coronary vasodila-
tion,73 and in an animal model of cardiomyopathy,
long-term treatment with quinapril resulted in a sig-
nificant cardioprotective effect.74 These data provide
strong evidence for the functional significance of the
cardiac renin–angiotensin system in both patients with
heart disease and in controlled experimental situa-
tions.
In 2 studies, the effects of ACE inhibition (ramipril
or fosinopril) on survival in experimental aortic ste-
nosis were examined.59,71 This model allows the sep-
aration of peripheral and cardiac drug effects, because
afterload reduction is prevented by a clip at the as-
cending aorta. Both studies demonstrated a survival
benefit in animals receiving the ACE inhibitor, thus
suggesting that the inhibition of cardiac ACE contrib-
utes to the prognostic relevance of these agents in
patients with heart failure.75,76
Role of tissue ACE in the vasculature: REGULATION OF
VASCULAR ACE: ACE is the most important enzyme
controlling the activation of angiotensin and the deg-
radation of bradykinin.77 Although ACE is widely
distributed through the tissues, it appears that ACE
expression is regulated by a number of different mech-
anisms. In cultured endothelial cells, the expression of
ACE is modulated by steroids, calcium ionophores,
and growth factors.78 The expression of ACE in en-
dothelial cells and culture is also a function of con-
fluence, as ACE enzyme levels increase exponentially
after confluence is obtained.79 Thus, the regulation of
endothelial ACE is a determinant of vascular function
in both health and disease.
Studies of Ang I infusion into human forearm or
coronary arteries have shown that Ang I is converted
to Ang II. This conversion is blocked by ACE inhib-
itor treatment. The primary vasodilatory action of
ACE inhibitors is the blockade of Ang II formation.
The contribution of bradykinin to the action of ACE
inhibitors has been debated. With long-term adminis-
tration, ACE inhibitors lower blood pressure, even in
patients with low renin hypertension, suggesting an
effect that is independent of a decrease in Ang II.
Bradykinin is a potent vasodilator, acting through the
release of prostacyclin, nitric oxide, and endothelial-
derived hyperpolarization factor. Accurate measure-
FIGURE 3. Angiotensin-converting enzyme (ACE) inhibition and fibrinolysis. Inhibition of ACE prevents the degradation of bradykinin
and the formation of angiotensin II (Ang II), thus preserving fibrinolytic balance. Ang I  angiotensin I; PAI-1  plasminogen activa-
tor inhibitor type 1. (Adapted with permission from Circulation.160)
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ment of bradykinin concentrations in plasma has been
technically challenging; these concentrations have
been shown to be increased or unchanged after ACE
inhibition. Although it is clear that ACE inhibition
potentiates the hemodynamic effects of exogenous
bradykinin, this observation does not address whether
endogenous bradykinin plays a part in the action of
ACE inhibitors. Recent studies performed by Gainer
et al80 indicate that the coadministration of the brady-
kinin receptor antagonist, icatibant acetate (HOE 140),
significantly attenuates the hypotensive effect of cap-
topril. Although HOE 140 does not alter the renal
hemodynamic response to captopril, it does signifi-
cantly alter the change of plasma renin activity in
response to ACE inhibition. These effects appear to be
similar in both normotensive and hypertensive sub-
jects. These data confirm that bradykinin contributes
to the short-term effects of ACE inhibition in blood
pressure in normotensive and hypotensive persons and
suggest that bradykinin also contributes to the short-
term effects of ACE inhibition on the renin–angioten-
sin system. Similar results have been seen in the
effects of ACE inhibitors on endothelial vasodilator
function. Studies performed by Hornig et al81 have
shown that ACE inhibitors augment flow-dependent,
endothelial-mediated dilation in humans by a brady-
kinin-dependent mechanism.
ACE regulates other important vascular functions
(Figure 3). Studies in healthy human volunteers have
provided additional support for ACE in regulating
vascular fibrinolytic balance. Specifically, examina-
tion of the effect of activation of the renin–angiotensin
system by low salt intake (10 mEq vs 200 mEq so-
dium per day) on plasma fibrinolytic parameters dem-
onstrated that low salt intake was associated with a
significant increase in morning plasminogen activator
inhibitor type 1 (PAI-1) levels, and plasma PAI-1
correlated dramatically with serum aldosterone levels
(R  0.56, p 0.107). Treatment with quinapril
significantly lowered PAI-1 concentrations and the
molar ratio of PAI-1 to tissue plasminogen activator
throughout the day.82
PATHOPHYSIOLOGY OF VASCULAR ACE: The endothe-
lium plays a crucial role in the maintenance of normal
vascular tone and structure, local hemostasis, and vas-
cular-wall proliferation processes (Figure 4).83,84
These processes are mediated by the reactive release
of vasoactive substances (thromboxane A2, free radi-
cals, endothelin, prostacyclin) among which nitric ox-
ide is perhaps the most important. Nitric oxide (1)
relaxes vascular smooth muscle through a cyclic
guanosine monophosphate–mediated decrease in cy-
tosolic calcium, resulting in vasodilation; (2) mediates
coagulation by the inhibition of platelet aggregation
and the expression of adhesion molecules for both
monocytes and neutrophils; and (3) prevents structural
FIGURE 4. Origins and actions of vascular tissue angiotensin-converting enzyme (ACE)-angiotensin II (Ang II). FGF  fibroblast growth
factor; IGF  insulinlike growth factor; IL-6  interleukin-6; MCP-1  monocyte chemoattractant protein-1; PAI-1  plasminogen ac-
tivator inhibitor type 1; PDGF  platelet-derived growth factor; TGF-  transforming growth factor–.
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changes by inhibiting the growth and migration of
smooth muscle cells. These regulatory processes are
all subject to disruption by Ang II.
Ang II, elaborated by activated endothelial ACE,
impairs nitric oxide bioactivity, mainly because of
oxidative stress through the Ang II–induced produc-
tion of superoxide radicals (O2) that can scavenge
nitric oxide and reduce endothelium-dependent vaso-
dilation.85 This action is independent of the effects of
ACE in degrading bradykinin and modulating the
endothelial-dependent vasodilation in response to ac-
tivation of the 2-receptor.
There is evidence that ACE expression is increased
in atherosclerosis and that Ang II may contribute to
disease progression by increasing oxidative stress and
attenuating chemoattractant and adhesion molecule
expression, leading to inflammation. As discussed,
tissue Ang II can also exert proproliferative and pro-
thrombotic actions (Figure 4). Diet et al86 reported that
tissue ACE in human atherosclerotic plaque localizes
to regions of inflammatory cells, especially areas of
clustered macrophages and microvessel endothelial
cells. The accumulation of ACE and metalloprotein-
ase in the shoulder region of the vulnerable plaque
may contribute to increased local circumferential
stress and plaque instability. Thus, ACE accumulation
within the vascular lesions may be a factor in the
pathophysiology of coronary artery disease.
This hypothesis is underscored by the findings of
an elegant experiment in which endothelial nitric ox-
ide synthetase gene knockout mice developed athero-
sclerotic lesions in response to adventitial vessel-wall
injury.87 Wild-type mice with normal endothelial
function were able to produce nitric oxide and were
therefore protected from this effect. The evidence
cited above indicates that plaque ACE may be an
important target of ACE inhibitor action.
Tissue ACE and the kidney: The prominent role of
Ang II in renal physiology, as briefly outlined below,
renders the kidneys highly susceptible to injury caused
by the de novo production of Ang II. The kidneys,
under the regulation of Ang II and aldosterone, main-
tain the electrolyte balance in the body. Sodium ho-
meostasis, in particular, is maintained by the local
action of Ang II on both the proximal and distal
tubules. The filtration function of the kidneys is also
preserved during changes in systemic blood pressure
by local Ang II, which acts to constrict the afferent
and efferent glomerular arterioles. The efferent arte-
rioles are very sensitive to Ang II, and the resulting
vasoconstriction, together with prostaglandin-induced
vasodilation of the afferent arterioles, regulates intra-
glomerular pressure, thereby maintaining the glomer-
ular filtration rate.
Because Ang II is essential in normal kidney func-
tion, increases in the level of locally elaborated Ang II
frequently result in pathophysiologic conditions. In
renovascular hypertension, for example, filter function
of the ischemic kidney is compensated with afferent
vasodilation and efferent Ang II–induced vasocon-
striction. Renin production is greatly increased as
well. This response to injury increases blood pressure,
exposing the contralateral kidney to the sequelae of
systemic hypertension. Ang II also maintains the glo-
merular filtration rate in chronic renal failure regard-
less of the cause of tissue damage. Despite this com-
pensatory response, there is a progressive loss of renal
function that results in further Ang II–generated in-
creases in glomerular blood pressure and, therefore,
continuing injury to the remaining nephrons.88 Ang
II–induced glomerular hypertrophy89 and renal fibro-
sis90,91 escalate the response to injury into a destruc-
tive cycle, which ultimately concludes with complete
renal failure.
CLINICAL CONSEQUENCES OF TISSUE ANGIOTENSIN-
CONVERTING ENZYME INHIBITION
Based on experimental data, hypertension may be
associated with increased local Ang II production,
which may play an important role in vasoconstriction
and direct tissue pathology. Consequently, antihyper-
tensive therapy with ACE inhibitors not only controls
hypertension by interrupting the renin–angiotensin
system, but it has the added benefit of reducing the
risk associated with Ang II–induced disease pro-
cesses, including cardiovascular disease and renal fail-
ure. Thus, our evolving understanding of the role of
tissue ACE in cardiovascular and renal disease culmi-
nates with the therapeutic application of this knowl-
edge. In this context, the beneficial consequences of
tissue ACE inhibition may occur independently of
changes in blood pressure (ie, overt renin–angiotensin
system activation); therefore, the value of inhibiting
tissue ACE may extend to a broader range of patients
than are currently being treated.
TISSUE ACE INHIBITION AND
HYPERTENSION, DIABETES, AND
RENAL DISEASE
The hallmark of essential hypertension is nephro-
sclerosis, the first clinical sign of which is protein
(chiefly albumin) in the urine. Proteinuria is a princi-
pal predictor of cardiovascular disease in patients
without diabetes mellitus and with type 2 diabetes,92
as well as in progressive renal disease in type 1
diabetes, and in patients with overt diabetic nephrop-
athy.93 Treatment with ACE inhibitors has been
shown to consistently reduce proteinuria in these pa-
tients, as compared with other antihypertensive agents
that appear to have milder effects.94–96
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The lack of an antiproteinuric effect by other an-
tihypertensive agents that effectively reduce blood
pressure suggests that renal protection afforded by
ACE inhibitors may occur through a blood pressure–
independent mechanism. Support for this hypothesis
can be derived from examining large clinical trials and
evaluation of the high-risk groups that were treated for
hypertension.
Aggressive antihypertensive treatment in patients
with type 2 diabetes mellitus was assessed in a sub-
group analysis (n  1,148) of the United Kingdom
Prospective Diabetes study in which 758 patients
(tight control group, blood pressure 150/85 mm Hg)
were randomized to either an ACE inhibitor or a -
blocker (captopril or atenolol, respectively) as the
main treatment.97 A total of 390 patients were treated
less aggressively (blood pressure 180/105 mm Hg)
with the same antihypertensive drugs. This study dem-
onstrated that aggressively treated patients had clini-
cally important reductions in the risks of death or
complications associated with diabetes compared with
patients who were treated less aggressively regardless
of the antihypertensive agent used. In light of these
data, could further evaluation of high-risk patients
with modest reductions in blood pressure uncover
additional beneficial effects attributable to a specific
class of antihypertensive agent?
The Captopril Prevention Project (CAPPP) was
designed to compare the effects of ACE inhibition and
conventional therapy (diuretics and  blockers) on
cardiovascular morbidity and mortality in hyperten-
sive patients.98 A subgroup of 700 CAPPP patients
were at increased risk for cardiovascular complica-
tions caused by diabetes mellitus. A total of 337 of
these patients were randomized to captopril and 380 to
conventional therapy. Although those patients treated
with conventional therapy had significantly lower
blood pressure than did the patients who received
captopril, conventional therapy did not result in any
additional benefit for diabetes-related risk. Those pa-
tients treated with the ACE inhibitor had a 66% re-
duction in fatal and nonfatal MIs and a reduced fre-
quency of all cardiac events and total mortality. More-
over, within the entire study population (N 10,085),
the incidence of diabetes was lower in the captopril-
treated patients than in those who received conven-
tional therapy (relative risk 0.86, confidence interval
0.74 to 0.99, p  0.039).
Evidence from the Appropriate Blood Pressure
Control in Diabetes (ABCD) trial further supports the
advantage of ACE inhibitor therapy in high-risk pa-
tients.99 ABCD was a prospective, randomized,
blinded trial comparing the effects of moderate blood-
pressure control (80 to 89 mm Hg, target diastolic
blood pressure) with intensive control (75 mm Hg,
target diastolic blood pressure) on the incidence and
progression of diabetic vascular complications in hy-
pertensive patients. First-line antihypertensive therapy
with a dihydropyridine calcium antagonist (nisoldip-
ine) or enalapril was also evaluated. A clinically im-
portant and highly statistically significant difference in
the cardiovascular event rate was observed after 67
months of treatment in the hypertensive cohort. Pa-
tients treated with ACE inhibitor therapy had fewer
nonfatal MIs (chi-square test: p  0.001), all MIs
(chi-square test: p  0.001), and overall cardiovascu-
lar events (chi-square test: p  0.002) than patients
treated with the calcium antagonist. This relation was
maintained in both the moderate and intensive blood-
pressure control groups.99 Because of ethical consid-
erations, there was no placebo control group in this
study. Therefore, the difference between the ACE
inhibitor group and the calcium antagonist group can-
not be definitively ascribed to a beneficial effect of
ACE inhibition. It is possible that calcium antagonists
exerted a deleterious effect on this study population.
Comparisons with other studies,100–102 however, sug-
gest that the rate of MIs in the calcium antagonist
group is not different from these historical controls;
therefore, the results of the ABCD trial may be attrib-
uted to a protective effect of ACE inhibition rather
than to a deleterious effect of calcium antagonists.99
The blood pressure–independent renoprotective ef-
fects of ACE inhibition have been clearly established
in 2 large placebo-controlled clinical trials. The first
study was conducted to determine whether captopril
has kidney-protecting properties independent of its
effect on blood pressure in patients with diabetic ne-
phropathy.103 All patients had type 1 diabetes melli-
tus, proteinuria 500 mg/day, and serum creatinine
concentration 2.5 mg/dL. Patients already on con-
ventional antihypertensive therapy were randomized
to captopril (n  207) or placebo (n  202) and were
observed for 4 years. Doubling of baseline serum
creatinine concentration—the primary study end-
point—occurred in 43 patients who received placebo
and in only 25 ACE inhibitor–treated patients (p 
0.007), representing a risk reduction of 48%. Risk
associated with the combined secondary endpoints
(death, dialysis, and kidney transplantation) was re-
duced by 50%, and an aggregate analysis revealed
significantly less proteinuria in the captopril-treated
patients than in those patients who received placebo
(p  0.001). Over the course of the study, there was
no difference in blood pressure in those patients with
pre-existing hypertension who were randomized to
ACE inhibitor therapy (n 155) or placebo (n 153,
p  0.16). Among patients who were normotensive at
study entry, blood pressure was only marginally
higher in the placebo group (p 0.001). Because
blood pressure was not different between the groups
with hypertension, and 85% of the patients who
reached the primary endpoint were hypertensive, the
decreased progression of diabetic nephropathy most
likely occurred through a mechanism that is not de-
pendent on blood pressure reduction.
Most recently, treatment with ramipril was found
to result in vasculoprotective and renoprotective ef-
fects in patients with diabetes who had a previous
cardiovascular event and at least 1 other cardiovascu-
lar risk factor.104 A total of 3,577 patients were ran-
domized to ramipril (10 mg/day) or placebo, and vi-
tamin E or placebo (22 factorial design). Treatment
with ramipril reduced the risk of overt nephropathy by
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24% (95% confidence interval 3 to 40, p  0.027),
and that of the combined primary outcome measure
(MI, stroke, or cardiovascular death), even after ad-
justing for changes in both systolic and diastolic blood
pressure, by 25% (confidence interval 12 to 36, p 
0.004).
These results extend to patients whose renal insuf-
ficiency stems from causes other than diabetic ne-
phropathy. The role of ACE inhibition in the preser-
vation of renal function in patients with mild-to-mod-
erate renal insufficiency because of diverse causes (eg,
nephrosclerosis, glomerular disease, diabetic nephrop-
athy) was evaluated using benazepril, an ACE inhib-
itor with high tissue-ACE affinity.105 A total of 583
patients were randomized to ACE inhibitor therapy
(n  300) or placebo (n  283). Renal insufficiency
was classified according to baseline creatinine clear-
ance as either mild or moderate (46 to 60 or 30 to 45
mL/min). The primary study endpoint was a doubling
of the baseline creatinine concentration or the need for
dialysis. At 3 years, the primary endpoint was reached
by 57 patients who received placebo and by 31 benaz-
epril-treated patients (p 0.001), yielding an extraor-
dinary overall risk reduction of 50%. Patients with
mild or moderate renal insufficiency had risk reduc-
tions of 71% and 46%, respectively. ACE inhibition
most effectively slowed the progressive deterioration
of renal function in patients with glomerular diseases;
however (and not unexpectedly), patients with poly-
cystic disease (who also do not respond to low-protein
diets) benefited the least.
Statistical adjustment for changes in blood pressure
among the benazepril-treated patients and those who
received placebo revealed that the risk reduction could
not be completely attributed to the antihypertensive
action of the ACE inhibitor. Additionally, the reno-
protective effect of benazepril, as reflected by reduced
urinary-protein excretion, was also found to occur
independently of changes in blood pressure.
CLINICAL ASPECTS OF TISSUE ACE
AND ITS RELEVANCE TO
CORONARY ARTERY DISEASE
ACE inhibitors as first-line therapy in patients with
heart failure, asymptomatic left ventricular dysfunction,
and in post-MI patients with a low ejection fraction:
More than 2 decades of experience have demonstrated
that ACE inhibitors save lives and decrease the num-
ber of hospitalizations in patients with heart failure,
asymptomatic left ventricular dysfunction, and those
post-MI patients with a low left ventricular ejection
fraction (Table 1).106–108 Consequently, ACE inhibi-
tors are now considered first-line therapy for these
patients.109 Benefits have been observed with different
ACE inhibitors, including captopril, enalapril, zofeno-
pril, ramipril, and trandolapril, thus suggesting a class
effect.
The Cooperative Northern Scandinavian Enalapril
Survival Study (CONSENSUS) demonstrated a sig-
nificant 40% reduction in 6-month mortality in enala-
pril-treated patients with severe heart failure versus
those patients who received placebo.75 Enalapril was
also found to reduce mortality in patients with less-
severe congestive heart failure. In the treatment arm of
the Studies On Left Ventricular Dysfunction
(SOLVD), enalapril significantly reduced overall mor-
tality by 16% versus placebo in patients with a left
ventricular ejection fraction of 0.35 and New York
Heart Association (NYHA) functional class II and
III.76 Whereas no mortality benefit was demonstrated
in the prevention arm of the SOLVD trials, which
enrolled asymptomatic patients with a left ventricular
ejection fraction 0.35, there was a significant reduc-
tion in hospitalizations for heart failure. The benefits
of ACE inhibitor therapy in heart failure are also
substantiated by a systematic overview of randomized
trials of ACE inhibitors in patients with heart fail-
ure.110 This meta-analysis of 32 trials, including 3,870
patients with symptomatic heart failure randomized to
ACE inhibitor therapy and 3,235 control patients,
reveals a 23% reduction in total mortality and a 35%
reduction in congestive heart failure in the ACE in-
hibitor group. Similar benefits were noted in this
meta-analysis across various subgroups defined by
age, sex, etiology of heart failure, and NYHA class.
Trials in patients with recent MI and moderate
reductions in the left ventricular ejection fraction in-
cluding the Acute Infarction Ramipril Efficacy
(AIRE) study,111 the Survival and Ventricular En-
largement (SAVE) trial,112 and the Trandolapril Car-
diac Evaluation (TRACE) trial,113 also demonstrate
significant mortality benefits for patients treated with
ACE inhibitors. The AIRE study evaluated ramipril
treatment in MI patients who had any sign of heart
failure subsequent to the MI.111 The risk of mortality
was decreased in the ramipril-treated patients by 27%
versus placebo. In a similar trial (SAVE), patients who
received captopril had a 19% reduction in mortali-
ty.112 In the TRACE study, patients who had an MI
with echocardiographic evidence of left ventricular
dysfunction and who were treated with trandolapril
had a 27% increase in life expectancy as compared
with patients given placebo.113
A recent systematic overview of long-term ACE
inhibitor therapy in patients with heart failure or left
ventricular dysfunction used pooled data from 12,763
patients randomly assigned to ACE inhibitor treatment
or placebo for an average of 35 months.109 In the 3
postinfarction trials included in this meta-analysis
(SAVE, AIRE, and TRACE), patients treated with an
ACE inhibitor had a 26% lower mortality, a 27%
lower rate of hospital admission for heart failure, and
a 20% lower reinfarction rate. Similarly, when, in
addition to the trials of patients with recent MI, trials
of patients with chronic heart failure or left ventricular
dysfunction were considered, significant reductions in
death, reinfarction, and heart failure rates were ob-
served in patients treated with an ACE inhibitor.
These benefits were observed early after the start of
therapy and persisted long term. Moreover, the bene-
fits of ACE inhibitor treatment were independent of
age, sex, and baseline use of diuretics, aspirin, and -
blockers.
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Finally, the results of 2 large studies and a com-
prehensive meta-analysis114 have firmly established
the benefits of ACE inhibition in acute MI patients.
The Fourth International Study of Infarct Survival
(ISIS-4) evaluated nearly 60,000 patients who were
randomized to oral mononitrate, intravenous magne-
sium sulphate, or captopril. Only captopril signifi-
cantly reduced mortality.115 The Third Gruppo Ital-
iano per lo Studio della Sopravvivenza nell’Infarto
Miocardico (GISSI-3) study randomized almost
19,000 patients to lisinopril or transdermal glycerin
trinitrate. Once again, only the ACE inhibitor was
effective, resulting in a 12% risk reduction in mortal-
ity.116
The effect of ACE inhibitors on MI and coronary
events: ACE inhibitors may also have the potential to
prevent major acute ischemic events, perhaps through
a mechanism that is independent of their ability to
lower blood pressure. The SOLVD and SAVE trials
have suggested that, in addition to reducing mortality
and hospitalizations for heart failure, ACE inhibitors
can also prevent major acute ischemic events when
administered long term in patients with a low left
ventricular ejection fraction.117,118 The reductions in
major acute ischemic events in these studies could not
be clearly explained by the acute hemodynamic ef-
fects of these agents. Furthermore, the reductions were
more pronounced than expected based on the attained
blood pressure lowering in these trials, thus suggest-
ing a direct tissue effect of ACE inhibitors to account
for the reductions in MI and unstable coronary syn-
dromes. Extending beyond this well-recognized class
effect, those ACE inhibitors with a high affinity for
tissue ACE may be especially beneficial in patients
whose conditions are not characterized by overt renin–
angiotensin system activation. In this regard, the tissue
effects of ACE inhibitors have been demonstrated in
both experimental models and human studies (1) to
restore endothelial function; (2) to have antiprolifera-
tive and antimigratory effects on smooth muscle cells,
neutrophils, and mononuclear lymphocytes; (3) to de-
crease oxidative stress; (4) to enhance endogenous
fibrinolysis; (5) to have antiplatelet effects; and (6) in
animals, to be antiatherogenic and capable of stabiliz-
ing plaque.119
Effects of ACE inhibition in high-risk patients with
coronary artery disease with preserved left ventricular
function: The Quinapril Ischemic Event Trial (QUIET)
trial enrolled1,750 patients who had coronary artery
disease but normal blood pressure and no hyperlipid-
emia.120 Patients were randomized to quinapril 20
mg/day or placebo for 3 years. Those receiving
quinapril had 13% fewer major vascular events,
which, although encouraging, did not achieve statisti-
cal significance. This trial, however, was hampered by
limitations, including patients who, overall, were at
low risk for major cardiovascular events at study
entry, and a high rate of drop-ins and dropouts. None-
theless, a post hoc analysis determined that patients
with low-density lipoprotein cholesterol elevated
above the study population’s median cholesterol levelT
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(130 mg/dL) had a statistically significant reduction in
the progression of coronary artery disease.121
The therapeutic implications of tissue ACE inhibi-
tion have been realized with the publication of the
Heart Outcomes Prevention Evaluation (HOPE) study
results.122 The HOPE study was a 22 factorial de-
sign trial, which randomized 9,541 high-risk patients,
55 years of age with evidence of vascular disease or
diabetes plus at least 1 additional cardiovascular risk
factor, in the absence of known heart failure or a low
left ventricular ejection fraction, to treatment with the
high tissue-affinity ACE inhibitor ramipril or vitamin
E 400 IU or placebo. The duration of therapy extended
over a mean period of 4.5 years and the primary study
outcome was the composite of MI, stroke, or death
from cardiovascular causes. Additionally, the HOPE
trial evaluated the effects of ramipril on each of the
components of the primary endpoint, namely MI,
stroke, and cardiovascular death as well as total mor-
tality, and it also evaluated the effects of therapy on
development of heart failure, the need for revascular-
ization procedures, and diabetes-related complica-
tions.
The study documented a highly statistically signif-
icant 22% reduction in the composite primary end-
point. Treatment with ramipril also reduced the rates
of death from cardiovascular causes by 25%, the risk
of MI by 20%, and the risk of stroke by a very
significant 31%. The risk for all-cause death was also
significantly reduced by 16%. Additionally, the study
demonstrated a reduction in heart failure, in revascu-
larization procedures, and in macro- and microvascu-
lar complications related to diabetes. Notably, there
was a 31% reduction in the diagnosis of new diabetes.
The dramatic reduction in major cardiovascular
events in the HOPE study was attained with only a
modest reduction in blood pressure in a patient pop-
ulation already treated with a variety of antihyperten-
sive medications, and in which most patients did not
have a history of hypertension. Thus, the mean reduc-
tion in systolic blood pressure was only 3.3 mm Hg
and in diastolic blood pressure, 2 mm Hg.
These modest reductions in blood pressure can
obviously not explain the large impact of therapy on
cardiovascular endpoints. Furthermore, similar bene-
fits were noted in patients with various levels of sys-
tolic and diastolic pressure at baseline and throughout
the study. These findings suggest that ramipril has
benefits over and above blood pressure lowering
alone, which may potentially be related to direct tissue
effects of the drug. Importantly, the beneficial effect
of treatment with ramipril on the composite outcome
was consistently observed among all predefined sub-
groups, including (1) patients with and without diabe-
tes, (2) women and men, (3) those with and without
evidence of cardiovascular disease, (4) those 65
years of age and those 65 years of age, (5) those
with hypertension at baseline and those without a
history of hypertension, (6) those with and without
microalbuminuria at baseline, (7) those with a history
of coronary artery disease and those with no such
history, and (8) in those patients with prior MI and
those without a history of MI. Although the relative
risk reductions among these subgroups were compa-
rable, the largest absolute benefit was derived in indi-
viduals with the highest baseline risk, including (1)
those with a history of diabetes, (2) those 65 years
of age, (3) those with a history of hypertension, and
(4) those with a history of prior peripheral vascular
disease or coronary artery disease. The benefits of
ramipril were observed among patients already taking
a number of effective treatments, including aspirin, -
blockers, and lipid-lowering agents, thus indicating
that the inhibition of ACE offers an additional ap-
proach to the prevention of atherothrombotic compli-
cations. Results of this landmark study strongly sup-
port the use of ACE inhibitor therapy in a broad range
of patients at high risk for adverse cardiovascular
events, independent of their left ventricular ejection
fraction and whether or not they had clinical manifes-
tations of heart failure. Therefore, all individuals with
a history of vascular disease affecting the coronary,
cerebrovascular, or peripheral vascular trees, and di-
abetic patients with additional risk factors should be
strongly considered for long-term ACE inhibitor ther-
apy. Among these patients, the greatest benefits may
be expected in those individuals with the highest base-
line risk for adverse cardiovascular outcomes.
The clear benefits demonstrated in the HOPE trial
in patients who usually do not have an activated
renin–angiotensin system, the uniformity of benefit
among different subgroups, and the magnitude of the
treatment effect—much larger than expected based on
the observed reductions in blood pressure—suggest
that the results of this study may indeed be explained
by inhibition of tissue ACE–mediated processes that
are related to atherosclerotic and ischemic complica-
tions. These findings are concordant with the results of
numerous laboratory investigations and clinical stud-
ies, such as the Trial on Reversing Endothelial Dys-
function (TREND),123 the Brachial Artery Normaliza-
tion of Forearm Function (BANFF),124 the Healing
and Early Afterload Reducing Therapy (HEART) tri-
al,125 and the effects of Quinapril on Vascular Ace and
Determinants of Ischemia (QUO VADIS) study,126
and support the use of ACE inhibitors that effectively
inhibit tissue ACE in a wide range of patients.
The effect of ACE inhibitor therapy on cardiovas-
cular outcomes in patients without heart failure and
with preserved left ventricular systolic function is also
being evaluated in large ongoing clinical trials. The
Prevention of Events with ACE Inhibition
(PEACE)127 and European Trial of Reduction of Car-
diac Events with Perindopril in Stable Coronary Ar-
tery Disease (EUROPA)128,129 trials, using the high
tissue-affinity ACE inhibitors trandolapril and perin-
dopril, and the Ischemia Management with Accupril
Post Bypass Graft via Inhibition of Converting En-
zyme (IMAGINE) study in patients with recent coro-
nary bypass graft surgery will provide further evi-
dence for the role of ACE inhibitor therapy in differ-
ent patient subsets. If these trials confirm the large
benefits noted in the HOPE study, this will further
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support the use of long-term ACE inhibitor therapy in
a wide range of patients with atherosclerotic disease
but without systemic activation of the renin–angioten-
sin system.
MECHANISTIC STUDIES WITH POSITIVE OUTCOMES:
Mechanistic studies using angiographic measurements
have yielded considerable evidence that endothelial
dysfunction can be altered or improved with various
ACE inhibitors and that there may be differences in
effects between these agents. With regard to tissue
ACE and its relation to coronary artery disease, the
most intriguing mechanistic studies include
TREND,123 BANFF,124 HEART trial,125 and the QUO
VADIS study.126
The TREND study was the first to show improved
endothelial function in coronary artery disease patients
who were normotensive but did not have severe hyper-
lipidemia or evidence of heart failure.123 A total of 105
secondary prevention patients were randomized to
quinapril 40 mg/day or placebo and observed for 6
months. Using quantitative coronary angiography, lumi-
nal diameter changes in response to acetylcholine were
measured in both cohorts at baseline and at study com-
pletion. After 6 months, patients in the quinapril group
showed significant improvement in endothelial response
over the placebo group (p 0.002), suggesting that ACE
inhibition attenuates the vasoconstrictive and superox-
ide-generating effects of Ang II while promoting endo-
thelial cell release of nitric oxide consequent to the
accumulation of bradykinin.
The BANFF study124 compared the effects of
quinapril 20 mg, enalapril 10 mg, amlodipine 5 mg, and
losartan 50 mg on blood flow and dilation of the brachial
artery. These doses were considered equal in antihyper-
tensive efficacy. Results were assessed by measuring
flow-mediated vasodilation of the brachial artery in re-
sponse to hyperemia through high-resolution intravascu-
lar ultrasound. Patients, who all had evidence of coro-
nary artery disease confirmed by angiography, were ran-
domized in a crossover design to 3 drugs for 8 weeks
each, with a 2-week washout period in between. Al-
though all of the agents improved blood pressure, they
differed in their ability to improve endothelial function.
Quinapril was the only agent that produced a significant
improvement (p 0.02) in endothelial function versus
baseline.
The HEART study,125 in which 120 patients were
randomized to ramipril (relatively high affinity for
tissue ACE) or placebo within 24 hours of the onset of
symptoms of MI, observed a significant decrease in
PAI-1 activity levels with the administration of the
ACE inhibitor. This finding supports an earlier sup-
position that the renin–angiotensin system plays an
important role in regulating endogenous fibrinolysis
and that ACE inhibition may decrease the increase in
PAI-1, yielding a clinical benefit.125 Similar results
were also reported with the use of captopril post
MI.130
STUDIES EVALUATING THE EFFECTS OF ACE INHIBITION
ON THE ANATOMIC PROGRESSION OF ATHEROSCLEROSIS:
The effects of long-term ACE inhibition on the ana-
tomic progression of atherosclerotic lesions of the
coronary and carotid arteries were evaluated (Table 2)
in the QUIET study,120 the Simvastatin Coronary Ath-
erosclerosis Trial (SCAT),131 the Prevention of Ath-
erosclerosis with Ramipril Therapy-2 (PART-2),132
and the Study to Evaluate Carotid Ultrasound Changes
in Patients Treated with Ramipril and Vitamin E (SE-
CURE).133 In the PART-2 trial, atherosclerotic pro-
gression was measured by B-mode carotid ultrasound
of the extracranial carotid arteries; quantitative coro-
nary angiography was used in SCAT. These studies
were considered “neutral” because they did not pro-
vide clear evidence that ACE inhibitors can delay or
reverse atherosclerotic lesions. Both PART-2 and
SCAT, however, which together observed 1,000
patients, demonstrated significant improvements in
rates of cardiovascular deaths, MI, and stroke. The
angiographic substudy of QUIET demonstrated lesser
progression of coronary atherosclerosis in patients
with elevated cholesterol concentration (low-density
lipoprotein cholesterol 3.2 mmol/L) treated with
quinapril, but no clear benefit in those with lower
low-density lipoprotein cholesterol levels. Finally, the
SECURE trial (a substudy of HOPE) showed that
ramipril 10 mg/day was effective in retarding the
progression of atherosclerosis as evaluated by B-mode
carotid ultrasound.134 These differences are likely re-
lated to diversity in the patients studied, the ACE
inhibitors used, and most importantly, the methods
used to assess the progression of the anatomic extent
of atherosclerosis.
TABLE 2 Long-Term Trials Examining the Effects of Angiotensin-Converting Enzyme (ACE) Inhibitors on Atherosclerotic Disease
Progression or Ischemic Events in Patients without Heart Failure or Low Ejection Fraction
Trial
ACE
Inhibitor Primary Outcome
Sample
Size (n)
Duration
(yr)
QUIET120 Quinapril 1. Quantitative coronary angiographic measures of CAD progression
2. Cardiac ischemic endpoints*
1,775 3
SCAT131 Enalapril Quantitative coronary angiographic measures of CAD progression 468 5
PART-2132 Ramipril B-mode ultrasound measures of carotid atherosclerosis 600 4
HOPE133 Ramipril Composite of myocardial infarction, stroke, or death from cardiovascular causes 9,297 5
CAD  coronary artery disease; HOPE  Heart Outcomes Prevention Study; PART  Prevention of Atherosclerosis with Ramipril Therapy; QUIET  Quinapril
Ischemic Event Trial; SCAT  Simvastatin and Enalapril Coronary Atherosclerosis Trial.
*Composite endpoint including cardiovascular death, nonfatal myocardial infarction, coronary revascularization procedures (coronary artery bypass graft surgery,
angioplasty, atherectomy), and hospitalization for unstable angina pectoris.
Adapted from Circulation.119
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PHARMACOLOGY OF ANGIOTENSIN-CONVERTING
ENZYME INHIBITORS
The ACE inhibitors currently number more than a
dozen different agents worldwide and have long been
represented by captopril and enalapril, the first ACE
inhibitors to be approved. Because the mechanism of
action of the ACE inhibitors is the same (ie, compet-
itive inhibition of ACE), the documented beneficial
effects of captopril and enalapril, among others, are
attributed to the class as a whole. Nevertheless, indi-
vidual ACE inhibitors have unique pharmacokinetic
properties that may result in differential clinical ef-
fects. The most important property, perhaps, is the
strength of binding affinity to tissue ACE.
The active catalytic sites of ACE consist of hydro-
phobic pockets of amino and carboxyterminal side
chains on the enzyme’s surface. The binding strength
of ACE inhibitors to ACE is dependent on the binding
of the sulfhydryl-, carboxyl-, or phosphinyl-contain-
ing group at the N-terminus of the ACE inhibitor with
the coordinated Zn2 as well as the binding of the
negatively charged C-terminus of the ACE inhibitor
with the postulated positively charged carboxylate
dock residue (believed to be an arginine side chain) of
ACE.135 The affinity of ACE inhibitors to ACE is also
dependent on the number of auxiliary binding sites,
the most important of which are the S’1 and S’2
subsites.136
RELATIVE TISSUE AFFINITY OF ACE
INHIBITORS
The degree of functional in vivo inhibition of tissue
ACE produced by an ACE inhibitor is directly depen-
dent on the binding affinity of the inhibitor and the
concentration of the free inhibitor in the tissue. The
concentration of the free inhibitor in the tissue, in turn,
is dependent on the dynamic equilibrium between the
rate of delivery of ACE inhibitor to the tissue and its
subsequent washout into the blood. Key factors affect-
ing the concentration of free inhibitor in tissues are
dose, bioavailability, half-life in blood, tissue penetra-
tion, and tissue retention (or depot effect). Bioavail-
ability and half-life in blood can readily be determined
and are important for decision making in initially
choosing the correct dose of ACE inhibitor. When
blood levels of the ACE inhibitor are consistently
high—normally in the first half of the dosing period—
tissue retention of the inhibitor is not likely to have a
significant effect on functional ACE inhibition. How-
ever, toward the end of the dosing period, as the levels
of the ACE inhibitor in blood decreases, 2 factors
appear to be key in producing functional tissue ACE
inhibition: (1) inhibitor binding affinity, and (2) tissue
retention (which will directly influence the concentra-
tion of the free inhibitor in the tissue).
The rank order of potency of several different ACE
inhibitors has been determined by investigators using
competition analyses31,137–139 and by direct binding of
tritium-labeled ACE inhibitors to tissue ACE.140 The
potency is: quinaprilat  benazeprilat  ramiprilat 
perindoprilat  lisinopril  enalaprilat  fosino-
pril  captopril. The potency of ACE inhibitors in
tissue may also be ranked accordingly (Table
3).31,106,138,141,142
Tissue retention of ACE inhibitor has also been
examined. Isolated organ bath studies examining the
duration of ACE inhibition after the removal of ACE
inhibitor from the external milieu shows that func-
tional inhibition of ACE lasts well beyond (2- to
5-fold longer) the time predicted solely on the basis of
inhibitor dissociation rates or binding affinity.140 In-
deed, inhibitors with similar dissociation rates from
tissue ACE show markedly different degrees of func-
tional inhibition or retentiveness after washout. The
rank order of tissue retentiveness is quinaprilat 
lisinopril  enalaprilat  captopril and reflects both
the binding affinity and lipophilicity of these inhibitors.
CAN ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
BE DIFFERENTIATED?
The physiochemical differences among ACE in-
hibitors that are responsible for their distinct pharma-
cologic properties—binding affinity, potency, li-
pophilicity, and depot effect—reveal that a divergent
trend allows the arbitrary classification of ACE inhib-
itors as agents according to tissue-ACE affinity (Table
3). Thus, the recognition that tissue ACE, the endo-
thelium, and the natural history of cardiovascular dis-
ease are interrelated leads to the question of whether
the degree of tissue-ACE inhibition may extend to
differences in efficacy. Clearly, a reduction of Ang II
and increased nitric oxide bioavailability may repre-
sent the mechanism by which ACE inhibitors confer
vascular protection. As a consequence, endothelial
function may be regarded as a surrogate marker for
vascular protection. The effects of ACE inhibitors on
endothelium-dependent relaxation appear to differ
among several reports and appear to be dependent on
the agents used and the experimental designs (Table
4).123,124,126,143–148 It is intriguing that consistent im-
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provement in endothelial function is reported with
those ACE inhibitors with higher tissue-ACE affinity,
such as quinapril and ramipril.
Ramipril has been shown to improve endothelial
dysfunction by attenuating the toxic effects of oxi-
dized low-density lipoprotein in vitro.149 More re-
cently, ramiprilat was found to prevent the develop-
ment of coronary endothelial dysfunction in a canine
model. In this model, scanning electron micrographs
of subepicardial arterioles from control dogs revealed
endothelial leukocyte adhesion and crater formation.
These markers of endothelial dysfunction were not
observed in ramiprilat-treated dogs.150 Likewise, per-
indopril prevented chronic heart failure–induced en-
dothelial dysfunction and reduced media cross-sec-
tional area and collagen density in rats.151 Perindopril
has also been shown to accelerate endothelial re-
growth after balloon denudation in rabbits.152 In hu-
mans, long-term treatment with perindopril inhibits
both endothelial and adventitial ACE in the internal
mammary arteries from patients with ischemic heart
disease.153
Several studies further extend these lines of evi-
dence, including the TREND123 and the BANFF124
studies (see above), which have established that tis-
sue-ACE inhibition improves endothelial function in
humans. Interestingly, the BANFF study showed that
enalapril and antihypertensive agents from other
classes have no effect on endothelial function.
These results are strengthened by those from QUO
VADIS,126 a 2-phase, parallel-arm, phase 3 study of
ACE inhibition in coronary artery disease patients
scheduled to undergo coronary artery bypass graft
surgery. Patients were randomized to a double-blind,
placebo-controlled treatment with quinapril (40 mg/
day), or a single-blind treatment with captopril 50 mg,
3 times a day (phase 1, before coronary bypass graft
surgery). Overall, 75 patients received quinapril, 37
received captopril, and 74 patients received placebo,
with treatment beginning, on average, 27 days before
coronary bypass graft surgery.
Phase 1 of QUO VADIS was designed (1) to
determine the effects of ACE inhibition with quinapril
and captopril on vascular tissue ACE, independent of
the circulating renin–angiotensin system and the for-
mation of Ang II; and (2) to determine whether func-
tional differences existed between the 2 ACE inhibi-
tors.126 During coronary bypass graft surgery, seg-
ments of internal mammary arteries were harvested
for in vitro measurements of tissue-ACE activity.
Both quinapril and captopril reduced the production of
Ang II. However, only the reduction in Ang II forma-
tion in quinapril-treated patients was significant (p
0.05) versus placebo. This result suggests that there
is a functional difference in the respective abilities of
quinapril and captopril to inhibit endothelial ACE and
the local production of Ang II. Phase 2 of the QUO
VADIS study126 evaluated the effect of chronic ACE
inhibition (quinapril, 40 mg/day for 1 year) versus
placebo, on the incidence of ischemia. Treatment with
quinapril significantly (p  0.02) reduced clinical
ischemic events during the 1-year period after coro-
nary bypass graft surgery.
The potential importance of tissue-ACE inhibition
was further demonstrated in a study of patients with
chronic heart failure by quantitating impaired flow-
dependent dilation as a measure of endothelial dys-
function.147 The effects of quinaprilat (high affinity to
tissue ACE) were compared with those of enalaprilat.
High-resolution ultrasound and Doppler were used to
measure radial-artery diameter and blood flow in pa-
tients who received intra-arterial infusions of
quinaprilat (1.6 g/min, n  15) and enalaprilat (5.0
g/min, n  15) while at rest and during reactive
hyperemia. Measurements were made both before and
after N-monomethly-L-arginine was used to inhibit
endothelial nitric oxide synthetase and, hence, the
production of nitric oxide. Quinaprilat improved flow-
dependent dilation by 40%, whereas enalaprilat had
no effect. Moreover, although endothelial nitric oxide
synthetase was inhibited by N-monomethyl-L-arginine
(the part of flow-dependent dilation mediated by nitric
TABLE 3 Pharmacological Properties of Various Angiotensin-Converting Enzyme (ACE) Inhibitors in Plasma and Tissue
Tissue
Potency*
ACE Inhibitor Potencies
(mmol/L  109, ID50)†
Enzymatic
Inhibition (IC50)‡
Radioligand
Displacement (DD50)‡
Plasma
Half-Life§
Relative Lipid
Solubility
High
Quinaprilat 0.07 5.5  1011 4.5  1011 25 
Benazeprilat NA 1.3  109 4.8  1011 11 
Ramiprilat 0.08 1.9  109 7.0  1011 50 
Perindoprilat 0.40 NA NA 10 
Lisinopril NA 4.5  109 1.7  1010 12 NA
Enalaprilat 1.00 4.5  109 1.1  109 11 
Fosinoprilat NA 1.6  108 5.1  1010 11.5 
Low
Captopril 15.00 NA NA 2 
NA  not available.
*Radioligand binding studies using the active drug moiety.31,138,141
†ID50 is the inhibitor concentration required to displace 50% of [
125I]531A bound to human plasma.142
‡Comparison of 50% inhibition of enzymatic activity (IC50) with 50% displacement of
125I-351A (DD50) from human plasma ACE.142
§Values cited for quinaprilat and ramiprilat are for dissociation from tissue ACE, ie, terminal half-life.106
Lipid solubility based on log P logarithm of the octanol/water partition coefficient of the active drug moiety, except for captopril;  signs represent increased lipid
solubility.142
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oxide), quinaprilat increased flow-dependent dilation
by 100%. Enalaprilat, even when infused twice, had
no effect. Similar results have been obtained with oral
administration of quinapril and enalapril.148 Thus, the
tissue affinity of quinaprilat may be a key to that
agent’s ability to improve endothelial-mediated dila-
tion.
This study also sheds light on the potential mech-
anism by which high tissue-affinity ACE inhibitors
improve endothelial-mediated relaxation. The mecha-
nism of increased nitric oxide activity may be the
result of enhanced bradykinin-mediated nitric oxide
release or reduced nitric oxide degradation by Ang
II–induced production of reactive oxygen species.85
Indeed, the latter mechanism has been demonstrated
by Harrison154 and Warnholtz et al,155 who also re-
ported that Ang II type 1 receptor blockade can reduce
superoxide anion production.
The supposition that high tissue-affinity ACE in-
hibitors may protect nitric oxide is authenticated by
Koh et al,156 who investigated the effect of quinapril
on brachial artery dilator responsiveness to increased
shear stress after ischemia induced in the forearm. The
study, essentially a bioassay for endothelial nitric ox-
ide available to vascular smooth muscle, measured
dilation by ultrasonography in 9 men with coronary
artery disease. Patients received quinapril, 20 to 40
mg/day, for 8 weeks. When compared with baseline
measurements, quinapril significantly increased flow-
mediated dilation (p 0.001), an effect that persisted
1 week after the discontinuation of therapy. Serum
nitrogen oxide levels (a measure of endothelial nitric
oxide release) were reduced nearly 20% (p 0.01),
suggesting that quinapril selectively improves endo-
thelium-dependent vasodilator responsiveness by in-
creased nitric oxide bioactivity in relation to vascular
smooth muscle in coronary artery disease patients.
Furthermore, this effect was achieved at a reduced rate
of nitric oxide release from the endothelium. Similar
results have been observed in patients with diabetes
who had received enalapril; however, the improve-
ment in endothelial function was not demonstrated
beyond 4 hours after dose.157 Therefore, high tissue-
affinity ACE inhibitors such as quinapril, perindopril,
and ramipril may increase bradykinin accumulation
and thus enhance nitric oxide release or reduce Ang
II–induced oxidant stress within the vessel wall, and
as a result, protect nitric oxide from superoxide anion
inactivation.156
Tissue ACE inhibition has also been shown to
promote angiogenesis in an ischemic hind-limb ani-
mal model by a process thought to involve the endo-
thelium. Ischemia was produced in 1 hind limb in
New Zealand White rabbits, which then received a
single intra-arterial injection of quinaprilat, captopril,
recombinant human vascular endothelial growth fac-
tor (positive control), or no treatment (negative con-
trol). Both functional and morphologic assessments
revealed augmented angiogenesis in quinaprilat-
treated rabbits, which was similar to that seen in
animals that received recombinant human vascular
endothelial growth factor and greater than that ob-
served in captopril-treated rabbits or the negative con-
trols. Residual ACE activity after quinaprilat and cap-
TABLE 4 Tissue Angiotensin-Converting Enzyme (ACE) Inhibition and Endothelial Function
Study ACE Inhibitor Population Outcome
Saris et al144 Enalaprilat Normotensive male volunteers Inhibition of contractile effects
of AI; reduction in fractional
conversion of AI to AII
Lyons et al148 Quinapril, enalapril Normotensive male volunteers Quinapril, but not enalapril,
significantly inhibited AII-
induced vasoconstriction
Padmanabhan et al145 Enalaprilat Normotensive male volunteers Enalaprilat failed to inhibit the
contractile response to AI
Hornig et al147 Quinaprilat, enalaprilat CHF patients Endothelial-dependent dilation
was improved with
quinaprilat, but not with
enalaprilat
Prasad et al146 Enalaprilat CAD patients Enalaprilat significantly
potentiated bradykinin-
mediated femoral
vasodilation
Mancini et al123 (TREND) Quinapril CAD patients with preserved LVF Increased coronary artery
dilation; increased
endothelial function in
smokers and those with
elevated LDL-C
Anderson et al124 (BANFF) Quinapril, enalapril,
losartan, amlodipine
CAD patients with preserved LVF Only quinapril significantly
improved endothelial
function
Oosterga et al126 (QUO VADIS-1) Quinapril, captopril CAD patients with preserved LVF Quinapril, but not captopril,
blocks AI conversion to AII
in vascular preparations
CAD  coronary artery disease; CHF  chronic heart failure; LVF  left ventricular function.
Adapted from Vascular Biology Working Group website.143
16L THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 88 (9A) NOVEMBER 8, 2001
topril was equivalent when measured in plasma but
was significantly reduced by quinaprilat in tissue
when compared with captopril (p 0.01).158
These results and those from HOPE122 support the
importance of tissue-ACE inhibition. Studies such as
IMAGINE, PEACE, and EUROPA, using quinapril,
trandolapril, and perindopril, respectively, may con-
firm the findings of the HOPE study and thus validate
the use of tissue-ACE inhibitors in clinical practice
among high-risk patient populations.
CONCLUSION
The experimental and clinical evidence presented
here validates earlier suppositions that long-term tis-
sue-ACE inhibition would provide important clinical
benefits to a broad population of patients with coro-
nary artery disease. The cardio- and renoprotective
benefits of this drug class appear to extend beyond the
therapeutic effects of blood pressure reduction and
may distinguish the ACE inhibitors from other anti-
hypertensive agents. The next significant step is to
determine if pharmacologic differences among the
ACE inhibitors, such as the affinity for tissue ACE
and the clinical effect on endothelial dysfunction, are
a differentiating factor within this class of important
cardiovascular drugs.
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